Filing Details

Accession Number:
0001127602-18-023315
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-07-16 20:20:07
Reporting Period:
2018-07-16
Accepted Time:
2018-07-16 20:20:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
318154 Amgen Inc AMGN Biological Products, (No Disgnostic Substances) (2836) 953540776
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1541946 E Sean Harper One Amgen Center Drive
Thousand Oaks CA 91320-1799
Evp, Research & Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-07-16 1,525 $195.71 56,082 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.
  2. These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,340 RSUs which vest in one installment on 1/30/2019; 3,000 RSUs which vest in installments of 1,477 5/3/2019 and 1,523 on 5/3/2020; 4,551 RSUs which vest in installments of 1,501 on 5/1/2019, 1,502 on 5/1/2029 and 1,548 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
  3. These shares include 495 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.